Zanidatamab – Talk Bio

Actionable Insights Powered by AI

Zanidatamab Demonstrates Promising 30-Month Survival Rate in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma

7 months ago talkbio0Tagged Antibodies, Bispecific, HER2-positive, Malignant neoplasm of stomach, Metastatic gastroesophageal adenocarcinoma, Neoplasms, Survival Rate, Zanidatamab

Zanidatamab, HER2-positive, metastatic gastroesophageal adenocarcinoma, bispecific antibody, survival rate, gastric cancer, oncology.

Jazz Pharmaceuticals Presents Groundbreaking HER2 Biliary Tract Cancer Data Ahead of FDA Decision

11 months ago talkbio0Tagged Biliary Tract Cancer, Decision, erbB-2 Receptor, Jazz, Priority Review, United States Food and Drug Administration, Zanidatamab

Jazz Pharmaceuticals, HER2, Biliary Tract Cancer, FDA Decision, Zanidatamab, Priority Review